Renaissance Technologies LLC Has $2.52 Million Position in LifeMD, Inc. (NASDAQ:LFMD)

Renaissance Technologies LLC increased its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 45.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 510,000 shares of the company's stock after buying an additional 158,796 shares during the quarter. Renaissance Technologies LLC owned 1.18% of LifeMD worth $2,524,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of LFMD. AXQ Capital LP purchased a new position in LifeMD during the 4th quarter valued at about $57,000. Quantbot Technologies LP purchased a new position in LifeMD during the fourth quarter valued at approximately $59,000. Prudential Financial Inc. lifted its position in LifeMD by 19.3% in the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock worth $67,000 after buying an additional 2,200 shares in the last quarter. Magnus Financial Group LLC boosted its stake in shares of LifeMD by 31.1% during the 4th quarter. Magnus Financial Group LLC now owns 16,000 shares of the company's stock valued at $79,000 after buying an additional 3,792 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in shares of LifeMD by 44.7% during the 4th quarter. Wells Fargo & Company MN now owns 18,732 shares of the company's stock valued at $93,000 after acquiring an additional 5,791 shares in the last quarter. 35.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price objective on shares of LifeMD in a report on Tuesday, March 11th. KeyCorp reduced their price target on LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. B. Riley upgraded LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. Finally, HC Wainwright raised their price objective on shares of LifeMD from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $11.00.

Insider Buying and Selling

In other LifeMD news, CMO Jessica Friedeman sold 30,000 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the completion of the sale, the chief marketing officer now directly owns 170,000 shares of the company's stock, valued at $962,200. This represents a 15.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $7.55, for a total value of $377,500.00. Following the transaction, the chief executive officer now owns 2,653,715 shares in the company, valued at $20,035,548.25. This represents a 1.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.97% of the stock is owned by insiders.

LifeMD Price Performance

Shares of LFMD stock traded up $0.01 during trading on Monday, reaching $6.10. The company had a trading volume of 541,467 shares, compared to its average volume of 814,128. The firm's 50 day simple moving average is $5.46 and its two-hundred day simple moving average is $5.48. LifeMD, Inc. has a one year low of $3.99 and a one year high of $12.88. The company has a market capitalization of $271.96 million, a PE ratio of -9.53 and a beta of 2.22.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The firm had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. Analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.